Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.
about
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotypePaediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlookAquaporin-4 autoimmunityInternational consensus diagnostic criteria for neuromyelitis optica spectrum disordersChallenges and opportunities in designing clinical trials for neuromyelitis opticaMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeNeuromyelitis optica: clinical features, immunopathogenesis and treatment.[Contribution of spinal cord biopsy to the differential diagnosis of longitudinal extensive transverse myelitis].Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria.Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS.Differential diagnosis of neuromyelitis optica spectrum disorders.Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate.Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.The frequency of anti-aquaporin-4 Ig g antibody in neuromyelitis optica and its spectrum disorders at a single tertiary referral center in malaysia.Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in cerebellar ataxia.MOG antibody-associated diseasesUpdate on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration.The growing spectrum of antibody-associated inflammatory brain diseases in children.Demographic and clinical features of neuromyelitis optica: A review.Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection.Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis.Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disordersMulticentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis opticaMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica.Syndrome of inappropriate antidiuretic hormone secretion associated with seronegative neuromyelitis optica spectrum disorder.Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study.The investigation of acute optic neuritis: a review and proposed protocol.Pain in neuromyelitis optica--prevalence, pathogenesis and therapy.Ocular manifestations in systemic lupus erythematosus.Body fluid biomarkers for multiple sclerosis--the long road to clinical application.Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.Neuromyelitis Optica Spectrum Disorder with Tumefactive Demyelination mimicking Multiple Sclerosis: A Rare Case.Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy.
P2860
Q21146662-81147115-C7B6-40A2-BD34-C3549ACD4126Q26748229-0ADF9562-4135-4655-A291-6AB7457BBB9FQ26786089-2018484E-1286-49A2-B36D-BA62FEA53389Q26799559-63228387-A14A-4A7F-8ED0-EEAB0737A933Q26824579-6BD6BC20-002B-48AF-BDE4-BCB09F71A717Q26999708-D99872D2-6494-4814-87DF-20E2C5E616B1Q30371412-51A8CEF4-A764-42CC-A6FC-E046FBE91535Q30785267-B15C12A5-A13A-4667-B21F-3023D937C624Q30844319-9189407A-4C7C-4DC4-A514-426837964FD7Q33567268-DB636E98-94FF-45B9-AB4C-B917774D5064Q33808279-E67A541D-4AB0-469F-8AF8-62D7A00C024DQ33812063-FEA552E0-31A4-4A30-AE82-40207CCE0C9CQ34026880-9A5370E8-F78A-4388-8DED-1D3E42CEA583Q34513731-6E7F93EA-C4D7-4E79-AD36-9A73AD467DBCQ34762744-AE0E1C29-B716-47C3-94C5-06C50EFAE363Q34990974-0F1E1636-B5CB-4758-97B8-6E9476D82649Q35023345-90935C1E-5BE3-447C-979C-3BE171111B66Q35052199-5F29F2D3-53FF-48B2-9AC4-25BC69E0E737Q35134856-A62A1486-5FFE-4BCF-9628-95FBDFD5F408Q35441181-9D777B02-EAFA-49A7-A5BD-6F3B684F642BQ35718428-01E202B1-91BA-4C42-ACB7-BAF1E4C539AEQ35850484-13A7FB78-1AF5-4625-91B1-CCF969C3A6D6Q36562604-73969895-FC0F-46B0-B794-97E6E6764AD9Q37059594-DF72B4A3-D93D-431A-89A3-584C9F612C54Q37235868-77E7F479-B70A-4A3B-9C16-0373EA61BE56Q37374434-87E970F0-2341-4F1D-9070-D0C2B19AF168Q37383474-EEDE1386-2E83-4606-9107-ECC9F840A68EQ37383555-7A84DBBB-BA21-4344-A676-00622E433095Q37470003-93E388E3-DCF1-49D7-91FB-72748F85E714Q37674159-3210F95C-2583-4EA7-A34F-F283418A1470Q37717025-8CF8A4B8-C976-4920-8712-12F968F43550Q38227109-BAD2082E-5A71-46DE-8095-CB524FEF579BQ38235026-9C86C276-9FCD-402D-9C39-CD378D6827EFQ38436812-3A9F3B6C-E464-4189-8B56-999517EE866CQ38590773-E080D5B7-D76E-4B56-A9C1-53C1A3151A18Q38750021-FC834C2D-06FE-41BC-A8A7-40352726C609Q38831970-A7C71CE8-80F6-4305-9633-5118D77E8032Q40545113-3F5DDD3E-D331-4D77-AB99-7BAF1D9620EFQ41332248-0F7F53EB-FFCE-44FC-8D2F-7C6D345457D8Q41570018-3EC9EA62-7BA4-410B-89B4-2CA67B2C8415
P2860
Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Aquaporin-4 antibodies (NMO-Ig ...... ical review of the literature.
@en
type
label
Aquaporin-4 antibodies (NMO-Ig ...... ical review of the literature.
@en
prefLabel
Aquaporin-4 antibodies (NMO-Ig ...... ical review of the literature.
@en
P2860
P356
P1433
P1476
Aquaporin-4 antibodies (NMO-Ig ...... ical review of the literature.
@en
P2093
Brigitte Wildemann
Sven Jarius
P2860
P304
P356
10.1111/BPA.12084
P577
2013-11-01T00:00:00Z